Aldeyra Therapeutics (ALDX)
Develops RASP modulators and ophthalmology candidates for immune-mediated diseases.
Something off on this page? Send us feedback.
Develops immune-mediated disease therapies built around protein-system modulation, with reproxalap for dry eye disease and allergic conjunctivitis and ADX-2191 for retinal diseases. The business is pre-commercial, runs as a single reportable segment, and depends on FDA outcomes, AbbVie's reproxalap option, and consultant-supported execution.
Develops therapies for immune-mediated diseases through protein-system modulation, centered on reactive aldehyde species biology. The disclosed pipeline includes next-generation RASP modulators ADX-248 and ADX-246, late-stage reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for retinal indications including primary vitreoretinal lymphoma and retinitis pigmentosa.
Operates as a pre-commercial, single-segment biotech from Lexington, Massachusetts, with a very small employee base and consultant-supported clinical and manufacturing work. The near-term commercial path for reproxalap is concentrated around U.S. FDA review and an AbbVie option for rights across U.S. and non-U.S. markets.
Reproxalap and ADX-2191 have both received FDA Complete Response Letters tied to evidence of effectiveness, while releases said safety or manufacturing concerns were not identified. The business depends on regulatory clearance, AbbVie's option decision, and scaling the organization if reproxalap is commercialized without that collaboration.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Mar 18, 2026 | HC Wainwright & Co. | Downgrade | ||
| Oct 8, 2025 | Jefferies | Target | Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $45.1M · Total debt $143.4K · Total assets $47.5M · Shareholders' equity $37.9M
- Revenue
- $0
- Operating income
- −$5.9M
- Net income
- −$5.5M
No dividends on record.
| Institutions | 60.56% | 36.53M shares | |
|---|---|---|---|
| 114 holders · as of Jun 30, 2026 | |||
| Insiders | 3.56% | 2.15M shares | |
| 5 holders · as of Jun 5, 2026 | |||
| Other | 35.88% | 21.65M shares | |
| remainder | |||
60.33M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Knoll Capital Management, LLCInstitution | 9.08% | 5.48M | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 6.22% | 3.75M | as of Jun 30, 2026 |
Kingdon Capital Management, L.L.C.Institution | 4.40% | 2.65M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.92% | 2.36M | as of Jun 30, 2026 |
D. E. Shaw & Co., Inc.Institution | 3.22% | 1.94M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 3, 2026 | Todd C. Brady | director, officer: President and CEO | +250,000 | $1.67 |
| Mar 19, 2026 | Richard Douglas | director | +70,000 | $1.40 |
| Mar 18, 2026 | Michael Alfieri | officer: Principal Financial Officer | +5,000 | $1.42 |
- Bausch + Lomb
Large eye-health platform with MIEBO, XIIDRA, and dry-eye brands
- Alcon
Global eye-care leader with FDA-approved TRYPTYR for dry eye
- Harrow
Ophthalmic specialty platform scaling VEVYE in branded dry eye
- Oculis
Clinical ophthalmology peer with licaminlimab for dry eye
- Viatris
Global pharma parent of TYRVAYA and ophthalmology franchise
- OKYO Pharma
Clinical-stage dry-eye and corneal-pain peer with urcosimod
- Ocugen
Gene-therapy retinal peer targeting retinitis pigmentosa
- Kiora Pharmaceuticals
Retinal-disease biotech developing KIO-301 for RP
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aldeyra Therapeutics | $1.34 | −3.94% | $84.1M | — | — | — | — |
| Bausch + Lomb | $17.18 | −0.84% | $6.19B | — | 17.2 | 1.2 | +9.1% |
| Alcon | $65.36 | −0.35% | $31.99B | 50.5 | 17.2 | 3.0 | +7.5% |
| Harrow | $33.94 | −1.49% | $1.28B | — | 27.3 | 4.7 | +10.9% |
| Oculis | $10.30 | −3.87% | $612.3M | — | — | 2,073.2 | +16.8% |
| Viatris | $17.15 | −0.20% | $20.01B | — | 6.7 | 1.4 | +4.9% |
| OKYO Pharma | $1.34 | −1.11% | $51.8M | — | — | — | — |
| Ocugen | $0.9949 | −4.34% | $352.7M | — | — | 77.0 | +8.4% |
| Kiora Pharmaceuticals | $2.69 | −0.92% | $12.0M | — | — | — | — |
| Median | 50.5 | 17.2 | 3.8 | +8.7% |